Search results
Showing 61 to 75 of 104 results for dexamethasone
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)
Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
Discontinued Reference number: GID-TA10254
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued Reference number: GID-TAG511
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Dexamethasone and hydrocortisone are both corticosteroids; they have a role in treating COVID-19 in certain people.
In development Reference number: GID-TA11660 Expected publication date: TBC
Discontinued Reference number: GID-TA10353
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
Evidence-based recommendations on using coronary artery stents in adults.
Discontinued Reference number: GID-TA10171
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.
Discontinued Reference number: GID-TA10926
Discontinued Reference number: GID-TA10502